Dec 14, 2022, 07:00 ET AOC 1001 delivered siRNA to skeletal muscle and produced meaningful DMPK reduction in 100% of participants with a 45% mean reduction in DMPK after a single dose of 1 mg/kg or two doses of 2 mg/kg AOC 1001 produced splicing improvement of…
Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7 The poster and oral presentations will include additional safety and efficacy…
Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immu... Novastra Therapeutics to Present First-in-Human Data for OAP-101 in Checkpoint-Refractory Advanced Melanoma at SITC 2026 Annual Meeting - Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP…
A new review outlines how lipid-based nanomedicines could deliver pathway-specific siRNA to treat hepatocellular carcinoma, highlighting delivery design, preclinical candidates and clinical constraints.
Moderna Chief Executive Stéphane Bancel thinks investors are wrong about the company’s cancer vaccine. Moderna’s stock fell sharply over the past few days after data emerged about its cancer vaccine that investors found disappointing, though researchers called it breakthrough. Bancel…
2026-10-28. The following slide deck was published by Moderna, Inc. in conjunction with this event.
Moderna (MRNA) and Merck (MRK) just released trial results for their joint vaccine against melanoma, the deadliest form of skin cancer. The results were positive, and even doctors praised the news. However, investors reacted differently to the news. On October…
A new review synthesizes evidence that gut microbiota composition and metabolites such as short-chain fatty acids modulate immune responses to mRNA vaccines, while cautioning that most data remain observational.
The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu vaccines. On August 5, the US Food and Drug Administration approved Moderna’s mFLUSIVA, the first influenza vaccine to use…
Oppenheimer cut Dyne Therapeutics to perform, citing small trial size and data risk for DYN-101 in DM1. - Oppenheimer downgraded Dyne Therapeutics (DYN) to perform from outperform, saying that upcoming data for DYN-101 (zeleciment basivarsen, or z-basivarsen), its candidate for myotonic dystrophy…
Medicines and vaccines made of RNA: mRNA vaccines and cancer vaccines, siRNA, antisense and RNA-editing drugs, and the companies developing them.
An article joins this feed when it matches these terms. Each one is also a search of its own.